What Syrinx Bioanalytics does

Syrinx Bioanalytics is a contract research organization headquartered in Turku, Finland, specializing in bioanalysis and immunogenicity testing for biological drugs, vaccines, and biomarkers. The company operates within the Synexa Life Sciences network of three GMP/GCP/GCLP-accredited laboratories located in Manchester (UK), Turku (Finland), and Cape Town (South Africa), employing 200+ staff of which 120+ are scientists with over two decades of cumulative biomarker and bioanalytical experience. The Turku facility specifically is GMP/GLP-accredited for radiopharmaceutical bioanalysis, handling radioisotopes including Ac-225, Th-227, and I-131, with 15+ years of specialized expertise in this niche.

The company delivers a multi-platform technology stack spanning mass spectrometry (LC-MS/MS, ICH M10-validated), immunoassay (MSD, ELISA, RIA), Olink proteomics (Proximity Extension Assay analyzing up to 92 proteins from 1 µL of sample), high-parameter flow cytometry (CLSI H62), ELISpot/Fluorospot, genomics (qPCR, ddPCR, SNP, targeted sequencing), multiplex tissue imaging (immunofluorescence, super-resolution microscopy, CLEM), and dose formulation analysis. Services are organized around three core offerings: translational services that validate therapeutic biology in human disease models prior to clinical entry, soluble biomarker custom panel development for Phase I through approval decisions, and regulated bioanalysis supporting PK, TK, PD, and immunogenicity endpoints. Therapeutic verticals served include autoimmune, oncology, vaccines, biosimilars, ADCs, and cell therapies.

Revenue is generated through professional services delivered as project-based, quote-driven contracts typically structured as multi-year engagements, with pricing varying by study complexity, sample volume, assay type, and regulatory compliance tier. The go-to-market relies on direct enterprise sales using a consultative scientific engagement model, supported by digital content marketing via LinkedIn, YouTube, the Synexa Insights blog, webinars, and industry conferences. The customer base consists of pharmaceutical and biotechnology companies (primary) and vaccine developers, with regulatory credentials including GLP/GCP compliance, GCLP accreditation, ICH M10 validation, GMP certification for radiopharmaceuticals, Gyrolab CRO Certification (June 2025), and My Green Lab highest-level certification (February 2025) forming the core barrier-to-entry for regulated work.

Name

Syrinx Bioanalytics

Legal name

Synexa Life Sciences

Website

https://syrinxbioanalytics.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

Syrinx Bioanalytics is a Finnish CRO based in Turku specializing in bioanalysis and immunogenicity testing for biological drugs, vaccines, and biomarkers, operating within the Synexa Life Sciences global network of three laboratories across the UK, Finland, and South Africa.

Ownership category

akta.pro rank

Product category

Bioanalytical Contract Research Organization (CRO) Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)

akta.pro secondary industries

Clinical CROs (Phase I–IV) (HLAGAAAA), Proteomics & Biomarker Analytical Testing (HLAGADAG)

Keywords

• Bioanalytical CRO services
• Immunogenicity testing
• Biomarker assay development
• Biological drug analysis
• Vaccine bioanalysis

Headquarters

HQ city

Turku

HQ country

Finland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Biomarker Services: Custom biomarker panel development, validation, and analysis services supporting target engagement, pathway modulation, and disease activity measurement from Phase I through approval
2. Regulated Bioanalysis: Bespoke bioanalytical method development and validation for PK, TK, PD, immunogenicity, and related endpoints with GLP/GCP compliance for regulatory submissions
3. Technology Platform Services: Specialized analytical services including mass spectrometry, immunoassay, flow cytometry, genomics, proteomics, and tissue imaging delivered as fee-for-service

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Syrinx Bioanalytics is a contract research organization (CRO) that provides bioanalysis and immunogenicity testing services for biological drugs, vaccines, and biomarkers. The company develops and validates custom-designed assays across multiple analytical platforms (mass spectrometry, immunoassay, flow cytometry, proteomics, genomics, tissue imaging, and radiopharmaceutical bioanalysis) to support pharmaceutical and biotech clients from discovery through regulatory submission. Operations are anchored in Turku, Finland, with broader laboratory capabilities spanning Manchester, Turku, and Cape Town delivering GLP/GCP/GCLP/ICH M10-compliant services.

Product overview

Synexa Life Sciences is a biomarker and bioanalytical CRO offering an integrated portfolio of laboratory services organized into three main areas: Translational Services (validating therapeutic biology in human disease models), Soluble Biomarkers and Regulated Bioanalysis (custom assay development and validation), and a suite of technology platforms including Mass Spectrometry, Immunoassay, Proteomics (Olink), Flow Cytometry, ELISpot, Radiopharmaceutical Bioanalysis, Genomics, and Tissue Imaging. The company operates three global laboratories in Manchester, Turku (Finland), and Cape Town with over 200 staff and 120+ scientists, providing end-to-end support from discovery through regulatory submission.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Reduce clinical trial risk by validating therapeutic biology in human disease models before entering clinic
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Waters CorporationcoreTechnology or Integration · 10 June 2025Synexa Life Sciences partnered with Waters Corporation as one of the first bioanalytical laboratories to trial the Xevo TQ Absolute XR Mass Spectrometer. This collaboration enables evaluation of next-generation LC-MS/MS technology for enhanced bioanalytical capabilities in small molecule, peptide, protein, and ADC quantification.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Celerion: Early-phase clinical and bioanalytical CRO with strong immunogenicity and PK assay capabilities for biologics and vaccines. Comparable niche focus on regulated bioanalysis supporting small- and large-molecule sponsors.
• KCAS Bioanalytical & Biomarker Services: Specialist bioanalytical CRO providing LC-MS/MS, ligand-binding, and biomarker services supporting PK, immunogenicity, and cell/gene therapy programs. Directly comparable in service mix and customer profile to Syrinx Bioanalytics.
• BioAgilytix Labs: Specialized bioanalytical CRO focused on large-molecule PK, immunogenicity, and biomarker assays for biologics and gene/cell therapies. Closely comparable to Syrinx in modality mix (immunoassay, LC-MS/MS), therapeutic focus, and sponsor base.
• Bionova Scientific: Specialized biologics-focused bioanalytical and GMP testing CRO offering cell-based assays, immunoassays, and lot-release testing for biologics developers. Comparable in modality focus and sponsor profile.
• Svar Life Science: Nordic-origin specialty CRO focused on immunogenicity, biomarker, and cell-based assay services. Highly comparable niche positioning to Syrinx, particularly in regulated immunogenicity testing.

Broad incumbents

• Charles River Laboratories: Large CRO with substantial bioanalytical and immunogenicity service lines serving biologics and vaccine developers. Comparable in offering but much broader portfolio, scale, and sponsor relationships than Syrinx.
• Eurofins Bioanalytical Services: Global CRO network offering large-molecule bioanalysis, immunogenicity, and biomarker services as part of a broader laboratory services portfolio. Comparable in assay capabilities but operates at significantly greater scale and geographic reach.
• Labcorp Drug Development: Full-service CRO with integrated bioanalytical, biomarker, immunogenicity, and central laboratory services for global clinical trials. Comparable capability set but competes via bundled, scale-driven offering.
• Pharmaron: Global CRO/CDMO with growing bioanalytical and biomarker service lines supporting biologics and vaccine programs. Comparable assay capabilities but broader service portfolio and larger scale.

Emerging players

• Immunologix Laboratories: Specialist bioanalytical CRO focused on immunogenicity, ADA, and cell-based assay services for biologics developers. Comparable niche in regulated immunogenicity testing, though smaller and earlier-stage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCHOFrAG_smPHVJ04pR7uEOA
• LinkedInlinkedin.com/company/syrinx-bioanalytics

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Syrinx Bioanalytics